Changes in body composition and leptin levels during growth hormone (GH) treatment in short children with various GH secretory capacities.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this clinical trial publication.

The aim of this study was to follow changes in body composition, estimated by dual-energy X-ray absorptiometry (DXA), in relation to changes in leptin during the first year of GH therapy in order to test the hypothesis that leptin is a metabolic signal involved in the regulation of GH secretion in children.

Who Took Part

The study group was 33 children.

PubMed indexes the participants as children and teenagers, both men and women.

In total, 33 prepubertal children were investigated.

Their mean (S.D.) chronological age at the start of GH treatment was 11.5 (1.6) years, and their mean height was -2.33 (0.38) S.D. scores (SDS).

How the Study Was Run

Ten children were in the Swedish National Registry for children with GH deficiency, and twenty-three children were involved in trials of GH treatment for idiopathic short stature.

In the 24-h GH profiles, the maximum level of GH was determined and the secretion rate estimated by deconvolution analysis (GHt).

Body composition measurements, by DXA, were performed at baseline and 12 months after the onset of GH treatment.

What Was Measured

PubMed files the paper under topics including Adipose Tissue, Body Composition, Body Height, Growth Disorders, Growth Hormone, Hormones and Human Growth Hormone.

What This Means in Plain Language

This is a clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 33 children.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1999 (European journal of endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.